



Remicade® (infliximab) – New warning

- On October 25, 2017, the FDA approved an update to the *Warnings and Precautions* section of the [Remicade \(infliximab\)](#) drug label regarding cardiovascular and cerebrovascular reactions during and after infusion.
- Remicade is indicated for adult and pediatric Crohn's disease, adult and pediatric ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
- Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of Remicade infusion. Cases of transient visual loss have been reported during or within 2 hours of infusion of Remicade.
 - Patients should be monitored during Remicade infusion and if serious reaction occurs, the product should be discontinued. Further management of reactions should be dictated by signs and symptoms.
- Remicade carries a boxed warning for serious infections and malignancy.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.